Abnormal: As variants spike, NYU Langone gets busy
By GREGORY ZELLER // “Normal” is back, at least for now – but COVID-19 is far from finished. Variants are thriving, millions remain unvaccinated (and are getting sick, or worse)…
National Institute of Allergy and Infectious Diseases
Innovation starts at the top – but it doesn’t end there
BY TERRY LYNAM // All organizations rely on their leaders for ideas that will set them apart from their competitors. But true innovators can be found at all levels of…
No. 560: Do you ever have déjà vu? Or loose change? Or bagels? Or déjà vu?
Stay tuned: You made it, dear reader – the end of another weak-in-the-knees workweek, with deadly pandemics and everything else overshadowed by the sickening schism in our nation’s capital….
Cold facts, with Dr. Fauci: Virus surging, but NYS ready
By GREGORY ZELLER // They’re thinking outside the box at different points along the COVID-19 vaccine distribution lines, and that includes New York State – where the thinking is decidedly…
NIH backs SBU-based biotech’s tuberculosis effort
By GREGORY ZELLER // A Setauket-based pharmaceuticals startup specializing in biomarker analysis has landed a chunky National Institutes of Health research award. Chronus Pharmaceuticals, founded and managed by researchers representing…
Codagenix scores again: $3M to hunt down deadly RSV
By GREGORY ZELLER // A fresh $3 million in public and private investments has set Codagenix Inc. on the trail of another nefarious disease. Already developing vaccines for Zika virus,…